

## Gastric cancer cell types display distinct proteasome/immunoproteasome patterns associated with migration and resistance to proteasome inhibitors

Francesca Monittola<sup>§</sup>, Marzia Bianchi<sup>§</sup>, Maria Gemma Nasoni, Francesca Luchetti, Mauro Magnani, Rita Crinelli\*

Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino (PU), Italy


<sup>§</sup>equally contributed

\*Corresponding author—Rita Crinelli


e-mail: [rita.crinelli@uniurb.it](mailto:rita.crinelli@uniurb.it)

ORCID: [0000-0002-1235-8910](https://orcid.org/0000-0002-1235-8910)


### SUPPLEMENTARY FIGURES




**Fig. S1** Proteasome and immunoproteasome activity in cell extracts obtained from cells treated with a toxic dose of BZ (50 nM) or ONX 0914 (500 nM) for 24h. Values are expressed as % of the control value (DMSO). Bars represent the mean  $\pm$  SD of the values obtained in n=2 independent experiments



**Fig. S2** Western immunoblotting analysis of cell extracts treated with ONX 0914 in the absence and presence of 50 μg/ml CHX for 16h



**Fig. S3** Proteasome and immunoproteasome activity in cell-free extracts obtained from cells treated for 24h with a non-toxic dose of ONX 0914 (100 nM). Values are expressed as % of the control value (DMSO). Bars represent the mean ± SD of the values obtained in n=2 independent experiments



**Fig. S4** Ubiquitin and Ub-conjugated proteins in ONX 0914-treated GC cells. Whole cell extracts (5  $\mu$ g) were resolved on a 13% (w/v) polyacrylamide gel and immunoblotted with an antibody against ubiquitin (Ub). On the left, arrows indicate the position of molecular weight markers